Jobs / United States / Regeneron Pharmaceuticals INC
Director, Publications
Regeneron Pharmaceuticals INC · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Regeneron Pharmaceuticals INC paid sponsored hires in similar roles13 certified filings for “Associate Director Imaging” (Natural Sciences Managers) in NY: $201k–$281k, median $225k. Most were filed at wage level II (69%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Regeneron Pharmaceuticals INC
The US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Regeneron Pharmaceuticals INC →
About the role
Build our future together: At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Director, Publications, to join our Medical Affairs team, supporting cross-functional and alliance-wide publication strategy for assigned therapeutic assets. In this role, you will lead the strategic direction and operational performance of publication plans while collaborating with authors, Medical Affairs partners, cross-functional collaborators, and external agency partners. This position offers the opportunity to contribute to a fast-growing, science-driven organization making a meaningful difference to patients worldwide. When & where: Location: Sleepy Hollow, NY or Warren, NJ Work model/flexibility: On-site 4 days/week. If based in Warren, NJ, travel to Sleepy Hollow will be expected. Discover your role : • Lead and accountable for cross-functional and alliance-wide publications teams. • Lead publications review of annual plans and projects with senior management • Lead in defining and building consensus on terms for literature and gap analyses to support scientific communication platform development and publication strategy • Pub plan and medical communication strategy development and evolution • Partner with procurement for agency selection and agency performance management • Budget accountability for agency external resource scope of work (SOW) development, budget tracking, and invoicing according to approved SOW/PO, reflecting work completed • Manage writers/agencies for individual pubs projects to effectively complete execution within specified timelines • Responsibility for alignment on scientific content/communication objectives, author invitations, collection of author agreements, securing medical/clinical lead materials for kick-off meeting discussions, author kick-off calls • Review assigned publications ensuring quality, alignment with scientific communication platform, and compliance with standards for ethical reporting of study data • Oversee efficient and compliant financial management • Ensure adherence to established compliance, regulatory, and ethical standards across all publication activities, including disclosure requirements, TOV guidelines, billing practices, and review documentation • Proactively identify and communicate operational risks, delays, or issues • Working with Executive Director, Publications identify and lead meaningful process improvements and innovations initiatives, as appropriate based on business needs This role requires: • Doctorate scientific degree required (PhD, PharmD, or MD) along with 7+ years of experience in medical communications or publications management within the pharmaceutical or biotechnology industry • Minimum 3 years of experience independently leading cross-functional, therapeutic area-specific publication plans • Proven track record managing complex, multi-asset publication plans, ideally within Oncology, Ophthalmology, Hematology, or Rare Diseases • Experience managing external agency partners and publication vendors, including budget oversight and SOW management Does this sound like you? Apply now to take your first step towards living the Regeneron Way! We are committed to building a workplace with an inclusive culture. Regeneron is an equal opportunity employer and all qualified applicants will receive consideration for employment without regard to race, color, religion or belief (or lack thereof), sex, sexual orientation, gender identity or expression, gender reassignment, marital or civil partnership status, civil status, pregnancy or parental status, age, disability, nationality, citizenship status, ethnic or national origin, membership of the Tr